Physician
Oncology
Dr. Lee J. Helman, MD
|
|
Give Review
Helman practices Oncology. He studied medicine at University of Maryland School of Medicine. University of Maryland School of Medicine has a rank of 37 in research and a 52 in primary care He received awards:"America's Top Doctors", "America's Top Doctors for Cancer", "Top Doctors:Baltimore Area", "Top Doctors:Washington DC Area", "Top Doctors:Washington-Baltimore", "Fellow (FASCO)", "Elected Member" and "Whos Who in Medicine and Healthcare". Lee J. Helman, MD is a published doctor as well. He has 57 publications published. The latest was: Perspectives from man's best friend: National Academy of Medicine's Workshop on Comparative Oncology.
Publications
- Risk-Based Therapy for Localized Osteosarcoma.
- Recurrent epimutation of SDHC in gastrointestinal stromal tumors.
- Quantitative determination of mithramycin in human plasma by a novel, sensitive ultra-HPLC-MS/MS method for clinical pharmacokinetic application.
- Imputation and subset based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33.
- New strategies in ewing sarcoma: lost in translation?
- A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteo...
- Dual Targeting of EWS-FLI1 Activity and the Associated DNA Damage Response with Trabectedin and SN38 Synergistically Inhibits Ewing Sarcoma Cell Growth.
- Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma.
- Genome-wide association study identifies two susceptibility loci for osteosarcoma.
- Cediranib for metastatic alveolar soft part sarcoma.
- Succinate Dehydrogenase Mutation Underlies Global Epigenomic Divergence in Gastrointestinal Stromal Tumor.
- Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation.
- Prospects and challenges for the development of new therapies for Ewing sarcoma.
- Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth.
- Expression of the receptor for type i insulin-like growth factor (IGF1R) in gastrointestinal stromal tumors: an immunohistochemical study of 1078 cases with diagnostic...
- Identification of FoxM1/Bub1b Signaling Pathway as a Required Component for Growth and Survival of Rhabdomyosarcoma.
- Gastrointestinal stromal tumor: psychosocial characteristics and considerations.
- Targeting the insulin growth factor receptor 1.
- Genomic investigation of dedifferentiated liposarcoma suggests a role for therapeutic targeting of the tumor epigenome.
- R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase I...
- Identification of an Inhibitor of the EWS-FLI1 Oncogenic Transcription Factor by High-Throughput Screening.
- Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
- Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer.
- Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.
- The role of IGF-1R in pediatric malignancies.
- Strategies to explore new approaches in the investigation and treatment of osteosarcoma.
- Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting an...
- Progress in the curative treatment of childhood hematologic malignancies.
- A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas.
- Hypocalcemia in a patient with osteosarcoma and 22q11.2 deletion syndrome.
- Osteosarcoma: the same old drugs or more?
- Dilemmas associated with congenital ewing sarcoma family tumors.
- The ubiquitin ligase gp78 promotes sarcoma metastasis by targeting KAI1 for degradation.
- The biology behind mTOR inhibition in sarcoma.
- Thromboembolic events in children and young adults with pediatric sarcoma.
- Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival.
- The molecular biology of pulmonary metastasis.
- CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcriptio...
- Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal transloc...
- Molecular approaches in pediatric oncology.
- Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells.
- Evaluation of the molecular mechanisms involved in the gain of function of a Li-Fraumeni TP53 mutation.
- Telomere stability genes are not mutated in osteosarcoma cell lines.
- The biology of metastases in pediatric sarcomas.
- Adjuvant chemotherapy for the treatment of advanced pediatric nonrhabdomyosarcoma soft tissue sarcoma: the National Cancer Institute experience.
- Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma.
- The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis.
- Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor.
- Tumor expression of 4-1BB ligand sustains tumor lytic T cells.
- Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis.
- Effect of insulin-like growth factor II on protecting myoblast cells against cisplatin-induced apoptosis through p70 S6 kinase pathway.
- Focus on sarcomas.
- Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels.
- A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluat...
- Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inte...
- Perspectives from man's best friend: National Academy of Medicine's Workshop on Comparative Oncology.
Schools
University of Maryland At Baltimore Professional Schools
Barnes Jewish Hospital
National Institute Of Health
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- Top Doctors:Baltimore Area
- Top Doctors:Washington DC Area
- Top Doctors:Washington-Baltimore
- Fellow (FASCO)
- Elected Member
- Whos Who in Medicine and Healthcare
Education
-
National Institutes of Health Clinical Center -
Washington University - Barnes-Jewish Hospital -
University of Maryland School of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Adrian M. Senderowicz, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Alain Thibault, MD |
|
|
Dr. J M. Hamilton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Osama Rahma, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ravi A. Madan, MD |
|
|
Dr. Robert J. Lechleider, MD
This Doctor is OpenDoctor Recommended.
|